Volver a Agenda
Session Chair(s)
Michael Swit, JD
Senior Director, Legal, Regulatory Affairs
Varian, United States
Learning Objective : Discuss how new technology leads to automatic Class III status for a device, even if not risky; Explain how the FDAMA created a new mechanism to avoid automatic Class III status by the de novo petition process; Examine the advantages and burdens of the process.
Speaker(s)
Overview of the De Novo Process
Michael Swit, JD
Varian, United States
Senior Director, Legal, Regulatory Affairs
The De Novo Pathway: Opportunities and Pitfalls - A Petitioner’s View from the Trenches
Michael Drues, PHD
Vascular Sciences, United States
Founder and President
¿Tiene una cuenta?